Bdx.Ax

BDX.AX has a current ratio of 2.32, indicating a moderate level of liquidity, but its operating cash flow of -6,135,890 AUD and free cash flow of -7,026,760 AUD suggest significant cash outflows. The company's debt-to-equity ratio of 0.38 reflects a relatively conservative capital structure, with long-term debt of 2,378,950 AUD compared to total equity of 6,220,920 AUD.

The company's profitability is severely challenged, with a return on equity of -1.164 and a return on assets of -0.7308, both well below industry norms. These metrics indicate that the company is not generating returns that meet the cost of equity or assets, which is a significant concern for investors.

BDX.AX's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification reported. This lack of diversification increases the company's exposure to market-specific risks and could impact its ability to sustain revenue growth.

The company's growth trajectory is negative, with a net income of -7,241,040 AUD and an operating income of -7,149,010 AUD. Analyst estimates for the upcoming period also project a mean revenue of 2,300,000 AUD and a mean EBIT of -8,300,000 AUD, indicating continued financial pressure.

The risk assessment for BDX.AX highlights medium liquidity risk and low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, suggesting potential challenges in meeting short-term obligations. The dilution risk is low, with no significant dilution sources identified in the available documents.

Recent events and filings for BDX.AX have not been disclosed in the available documents, limiting the ability to assess recent developments that may impact the company's financial position.

Becton Dickinson and Co (BDX.O) experienced significant volatility in its shareholder registry, marked by conflicting major severity signals regarding investor ID 587. Data detected on July 4, 2026, indicated a substantial increase in holdings for this investor, with shares rising from 7,723 to 161,749 as of March 31, 2026. This adjustment represented a shift in portfolio weight from approximately 0.0007% to 0.0147%, with the position value increasing from $1.21 million to $25.43 million. However, this upward revision was contradicted by an earlier signal detected on July 1, 2026, which recorded the inverse movement for the same investor and reporting period. That data point suggested a reduction in shares from 161,749 down to 7,723, implying a decrease in both share count and portfolio weight. A third signal, detected on June 27, 2026, also supported the higher share count of 161,749, creating a discrepancy in the chronological reporting of the investor's final position. In addition to these conflicting updates for investor ID 587, a notable addition to the shareholder list was recorded on June 28, 2026. Investor ID 933 was added to the registry with a position of 454,383 shares as of September 30, 2022. This holding represented a portfolio weight of 0.0317% and a value of $0.021 million, marking a distinct entry in the company's ownership structure. Despite these active changes in the holder registry, the broader material analysis for Becton Dickinson and Co showed no significant shifts. The company's fundamental profile, including its index membership and top holder count of 35, remained stable with no material changes detected against prior analysis. The observed activity is thus confined to specific investor reporting adjustments rather than a broader change in the company's financial or operational landscape.

Revenue grew 8.2% year-over-year to $21.84 billion in fiscal 2025, demonstrating strong top-line expansion.

Operating income increased 5.9% to $2.57 billion, reflecting improved operational efficiency and margin expansion.

Analysts project 16.8% upside to a mean price target of $182.67, signaling positive market sentiment.

Cash conversion of 3.01 ranks best-in-class among peers, highlighting superior capital management capabilities.

Operating and net margins exceed cohort medians, indicating stronger profitability than most medical equipment competitors.

The company carries a high credit risk flag, suggesting potential vulnerabilities in its financial stability.

Net income CAGR of -5.4% over four years indicates a long-term downward earnings trend.

Long-term debt increased to $20.11 billion in fiscal 2024, raising leverage concerns.

Return on equity of 4.48% remains relatively low, suggesting modest returns on shareholder capital.